APVO
Aptevo Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.01M
P/E Ratio
—
EPS
$-87.27
Beta
1.51
52W High
$486.00
52W Low
$3.84
50-Day MA
$6.06
200-Day MA
$25.19
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
3.89
PEG Ratio
0.00
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company is headquartered in Seattle, Washington.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 345,000 |
| EBITDA | $-26.07M |
| Operating Margin | 0.00% |
| Return on Equity | -234.60% |
| Return on Assets | -76.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $17.42 |
| Price-to-Book | 0.28 |
| Price-to-Sales (TTM) | 2.70 |
| EV/Revenue | 0.0011 |
| EV/EBITDA | 0.39 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $1.18M |
| Float | $1.18M |
| % Insiders | 0.06% |
| % Institutions | 1.88% |
Data last updated: 4/7/2026